New methodological approaches for assessing thrombus formation in cardiovascular disease

Kazuya Hosokawa; Tomoko Ohnishi-Wada; Tomoka Nagasato; Hisayo Sameshima-Kaneko; Chiaki Oyamada; Jeffrey Dahlen

doi:10.33963/KP.15493

New methodological approaches for assessing thrombus formation in cardiovascular disease

Kazuya Hosokawa, Tomoko Ohnishi-Wada, Tomoka Nagasato, Hisayo Sameshima-Kaneko, Chiaki Oyamada, Jeffrey Dahlen

Angiocardiology

Research output: Contribution to journal › Article › peer-review

Abstract

Antiplatelet therapy is the mainstay preventive strategy for cardiovascular diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is the standard treatment for patients who underwent percutaneous coronary intervention. The Total Thrombus‑Formation Analysis System (T‑TAS) is a microchip flow‑chamber system developed to evaluate overall thrombus formation under flow conditions, which is reportedly able to assess single and combined antithrombotic therapy. Here, we focus on this new system, T‑TAS, and review its characteristics together with those of the conventional systems available for evaluation of antithrombotic therapies for cardiovascular diseases.

Original language	English
Pages (from-to)	667-673
Number of pages	7
Journal	Kardiologia Polska
Volume	78
Issue number	7-8
DOIs	https://doi.org/10.33963/KP.15493
Publication status	Published - Aug 25 2020

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.33963/KP.15493

Fingerprint Dive into the research topics of 'New methodological approaches for assessing thrombus formation in cardiovascular disease'. Together they form a unique fingerprint.

Cite this

@article{b066fa08a79d47f78522c1c48f423e71,

title = "New methodological approaches for assessing thrombus formation in cardiovascular disease",

abstract = "Antiplatelet therapy is the mainstay preventive strategy for cardiovascular diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is the standard treatment for patients who underwent percutaneous coronary intervention. The Total Thrombus‑Formation Analysis System (T‑TAS) is a microchip flow‑chamber system developed to evaluate overall thrombus formation under flow conditions, which is reportedly able to assess single and combined antithrombotic therapy. Here, we focus on this new system, T‑TAS, and review its characteristics together with those of the conventional systems available for evaluation of antithrombotic therapies for cardiovascular diseases.",

author = "Kazuya Hosokawa and Tomoko Ohnishi-Wada and Tomoka Nagasato and Hisayo Sameshima-Kaneko and Chiaki Oyamada and Jeffrey Dahlen",

note = "Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine",

year = "2020",

month = aug,

day = "25",

doi = "10.33963/KP.15493",

language = "English",

volume = "78",

pages = "667--673",

journal = "Kardiologia Polska",

issn = "0022-9032",

publisher = "Klinika Kardiologii CMKP",

number = "7-8",

}

TY - JOUR

T1 - New methodological approaches for assessing thrombus formation in cardiovascular disease

AU - Hosokawa, Kazuya

AU - Ohnishi-Wada, Tomoko

AU - Nagasato, Tomoka

AU - Sameshima-Kaneko, Hisayo

AU - Oyamada, Chiaki

AU - Dahlen, Jeffrey

N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

PY - 2020/8/25

Y1 - 2020/8/25

N2 - Antiplatelet therapy is the mainstay preventive strategy for cardiovascular diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is the standard treatment for patients who underwent percutaneous coronary intervention. The Total Thrombus‑Formation Analysis System (T‑TAS) is a microchip flow‑chamber system developed to evaluate overall thrombus formation under flow conditions, which is reportedly able to assess single and combined antithrombotic therapy. Here, we focus on this new system, T‑TAS, and review its characteristics together with those of the conventional systems available for evaluation of antithrombotic therapies for cardiovascular diseases.

AB - Antiplatelet therapy is the mainstay preventive strategy for cardiovascular diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is the standard treatment for patients who underwent percutaneous coronary intervention. The Total Thrombus‑Formation Analysis System (T‑TAS) is a microchip flow‑chamber system developed to evaluate overall thrombus formation under flow conditions, which is reportedly able to assess single and combined antithrombotic therapy. Here, we focus on this new system, T‑TAS, and review its characteristics together with those of the conventional systems available for evaluation of antithrombotic therapies for cardiovascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=85090075973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090075973&partnerID=8YFLogxK

U2 - 10.33963/KP.15493

DO - 10.33963/KP.15493

M3 - Article

C2 - 32633476

AN - SCOPUS:85090075973

VL - 78

SP - 667

EP - 673

JO - Kardiologia Polska

JF - Kardiologia Polska

SN - 0022-9032

IS - 7-8

ER -